Anne Chiang, MD

Anne Chiang, MD, PhD, is an associate professor of medicine in the Section of Medical Oncology and the associate cancer center director of Clinical Initiatives at the Yale School of Medicine

Articles

Emerging Therapies for SCLC

October 30th 2025

Panelists discuss novel and investigational therapies under study for small cell lung cancer, including immunotherapy combinations and targeted approaches.

Experience With Lurbinectedin in SCLC

October 30th 2025

Panelists discuss real-world experiences with novel agents for relapsed small cell lung cancer, focusing on efficacy, safety, and patient selection.

Case 3: Second-Line Treatment for SCLC

October 30th 2025

Panelists discuss treatment decision-making in second-line small cell lung cancer, balancing efficacy, toxicity, and patient-specific factors.

Adherence to Treatment, Shared Decision-Making, and Patient Communication

October 30th 2025

Panelists discuss the importance of shared decision-making, patient communication, and adherence strategies in small cell lung cancer treatment.

Case 2: Treatment of Recurring SCLC With Brain Metastasis and AE Management

October 30th 2025

Panelists discuss therapeutic strategies for recurrent small cell lung cancer with central nervous system involvement, emphasizing adverse event (AE) management and patient support.

IMforte Trial: Applying the Results in Practice

October 30th 2025

Panelists discuss the clinical relevance of emerging trial data evaluating combination maintenance strategies and their potential role in practice.

Treatment Selection and Monitoring/Maintenance in Patients With SCLC

October 30th 2025

Panelists discuss practical considerations in selecting first-line regimens and managing maintenance therapy in patients responding to initial treatment.

Safety and Efficacy of SCLC Treatments Based on Trial Data

October 30th 2025

Panelists review key clinical trial data demonstrating the efficacy and safety of chemo-immunotherapy regimens in extensive-stage small cell lung cancer.

Introduction and Case 1: Diagnostic Workup of Patients with SCLC

October 29th 2025

Panelists discuss the diagnostic evaluation and staging process for extensive-stage small cell lung cancer, emphasizing comprehensive imaging and laboratory workup to guide initial treatment planning.

Treatment of SCLC Based on Patient Characteristics

October 29th 2025

Panelists discuss how patient and disease factors, such as performance status, comorbidities, and extent of metastases, influence first-line treatment selection in small cell lung cancer.

FDA Approval Insights: Maintenance Lurbinectedin Plus Atezolizumab for ES-SCLC: With Anne Chiang, MD, PhD; and Stephen Liu, MD

October 2nd 2025

Drs Chiang and Liu discuss the significance of the FDA approval of first-line maintenance therapy with lurbinectedin plus atezolizumab for ES-SCLC.

Chiang Contextualizes the Optimal Use of Lurbinectedin in SCLC Management

August 29th 2024

Dr Chiang discusses the use of lurbinectedin in small cell lung cancer and tips for managing toxicities associated with this agent.

Closing Thoughts and Key Takeaways on Small Cell Lung Cancer

August 6th 2024

In a forward-looking discussion, Ticiana Leal, MD; Anne Chiang, MD, PhD; Afshin Dowlati, MD; and Tarita O. Thomas, MD, PhD, offer their concluding insights on the evolving landscape of clinical trials and the future directions of small cell lung cancer (SCLC) treatment, highlighting promising areas of research and potential breakthroughs that may shape the management of this challenging disease in the years to come.

Examining Key Data from DAREON-8

July 30th 2024

Experts delve into the DAREON-8 Phase 1 clinical trial, assessing the potential impact of incorporating the study into the current treatment algorithm for small cell lung cancer (SCLC).

Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC

July 30th 2024

Medical experts review the Ideate-Lung02 phase 3 clinical trial, exploring the potential for ifinatamab to elicit durable responses in patients with advanced small cell lung cancer (SCLC), and discussing the implications of these findings for the future treatment landscape of SCLC.

DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival

July 23rd 2024

In a detailed analysis, key opinion leaders (KOLs) review the results of the DELLphi-301 Phase 2 clinical trial, assessing the efficacy of platinum-based chemotherapy in the treatment of small cell lung cancer (SCLC) and its impact on overall survival outcomes for patients enrolled in the study.

Navigating Later-Line Therapy Sequencing in LS-SCLC Progression

July 23rd 2024

In a focused discussion, Anne Chiang, MD, PhD, explores the sequencing of later-line therapies for limited-stage small cell lung cancer (LS-SCLC), emphasizing key factors to consider when making treatment decisions for patients who have progressed on initial therapy.

Dr Chiang on Frontline Treatment Combinations in ES-SCLC

May 25th 2023

Anne Chiang, MD, PhD, discusses treatment options for patients with extensive-stage small cell lung cancer.

Dr. Chiang on the Management of Immune-Related AEs in Lung Cancer

September 10th 2020

Anne Chiang, MD, PhD, discusses the management of immune-related adverse effects in lung cancer.

Project Patient Voice: A Milestone in Cancer Patient Empowerment

July 15th 2020

A new FDA program is giving patients and providers first-time access to patient-reported outcome data from cancer clinical trials of marketed treatments.